Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Growth in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 14,200 shares, a growth of 6.8% from the March 15th total of 13,300 shares. Based on an average daily volume of 18,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.1% of the shares of the stock are sold short.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Armata Pharmaceuticals by 59.5% during the fourth quarter. Vanguard Group Inc. now owns 145,078 shares of the company’s stock valued at $470,000 after acquiring an additional 54,109 shares during the period. Jane Street Group LLC bought a new stake in Armata Pharmaceuticals during the fourth quarter valued at about $25,000. Renaissance Technologies LLC raised its holdings in Armata Pharmaceuticals by 5.6% during the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock valued at $91,000 after acquiring an additional 3,900 shares during the period. HRT Financial LP bought a new stake in Armata Pharmaceuticals during the fourth quarter valued at about $52,000. Finally, Northern Trust Corp bought a new stake in Armata Pharmaceuticals during the first quarter valued at about $95,000. 3.57% of the stock is owned by institutional investors.

Armata Pharmaceuticals Price Performance

Shares of NYSEAMERICAN ARMP traded up $0.10 during midday trading on Wednesday, hitting $3.30. 1,054 shares of the stock traded hands, compared to its average volume of 17,036. Armata Pharmaceuticals has a one year low of $1.07 and a one year high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. The firm had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.68 million. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. Research analysts anticipate that Armata Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a report on Friday, March 22nd.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.